• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

ABBV STOCK HITS RECORD ALL TIME HIGH

Quote
anonymous said:
Besides pipeline tanking and impending Humira loss, the fact that AbbVie has 69.34 billion in total assets, offset by 65.79 billion in total liabilities is a recipe for disaster.

AbbVie Inc
NYSE: ABBV
$99.75 USD Down−0.42 (0.42%)
Click to expand...
Total nonsense re liabilities. That's a 'theoretical' number and has no relationship to the real world. If indeed there were any issue it would be mitigated in court. Do not worry my friend, ABBV is a blockbuster and you will do well if you own at $100/share. Many Wall Street gurus see $150 per share as a reasonable upside this year. Thankfully we have a strong CEO and corporate team running a tight ship, also loved by Wall Street and big pharma worldwide.
 












As shareholders we want regular reporting on how drug pricing risks are integrated into executive comp structures. Ricks salary needs to be decreased.

AbbVie Inc
NYSE: ABBV
$99.23 USD DOWN−0.40 (0.40%)
 
























anonymous said:
Just got back from my afternoon coffee, ABBV continues to move.

AbbVie Inc
NYSE: ABBV
$104.18 USD Up +1.33 (1.29%)
Click to expand...
Hey, I got pissed at him many times but he was a vet who suffered greatly and genuinely tried to serve his country. This crossed the line:

White House communications aide Kelly Sadler dismissed Sen. John Mcains's opposition to the confirmation of Gina Haspel as CIA director by saying, "It doesn't matter, he's dying anyway."

His daughter today addressed Sadler, "Kelly, there's a little news flash ... We're all dying. I'm dying; you're dying. We're all dying."
 








anonymous said:
In light of Trump's Big Pharma Pricing edict o Friday, ABBV continues to produce and move forward.

AbbVie Inc
NYSE: ABBV
$105.89 USD Up +1.71 (1.64%)
Click to expand...

So what else is new? This stock is headed to $150+ by 4Q18, my broker has maintained since last fall. I bought a ton (1000 + shares) at 92 so I expect a healthy reward.
 




















anonymous said:
As shareholders we want regular reporting on how drug pricing risks are integrated into executive comp structures. Ricks salary needs to be decreased.

AbbVie Inc
NYSE: ABBV
$99.23 USD DOWN−0.40 (0.40%)
Click to expand...

This is being looked at very closely and related to Citron's "dirty money" accusation.
Big surprise on ER coming Friday. Another cat will be let out of the bag.
 




anonymous said:
Not so fast genuises ! A few more adverse events or ANY negative results in trials of Rova-T, Elagoix, Upadacitinib, or Risankizumab combined with the clock ticking down on Humira could push this stock back to the $60s so fast your head will spin. Let's hope not, but smart investors won't EVER rule it out.
Click to expand...

Where do you get your inside info from? How could you know about this six months ago?
 












Top Bottom
Back
Quote